Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Eliem Therapeutics, Inc. (ELYM)
|
Add to portfolio |
|
|
|
| Price: |
$9.51
| | Metrics |
| OS: |
27.1
|
M
| |
|
|
| Market cap: |
$258
|
M
| |
|
|
|
Net cash:
|
$25.3
|
M
| |
$0.93
|
per share
|
|
EV:
|
$232
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($10.8)
|
M
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 0.0 | 26.2 | 0.0 | 23.3 | 0.0 | 2.5 |
| Revenue growth | | 12.4% | | | -100.0% | |
| Cost of goods sold | 0.0 | 45.1 | 0.0 | 35.7 | 0.0 | 2.5 |
| Gross profit | 0.0 | -18.9 | 0.0 | -12.4 | 0.0 | 0.0 |
| Gross margin | | -72.2% | | -53.0% | | 0.0% |
| Selling, general and administrative | 45.1 | | 35.7 | | 20.9 | |
| General and administrative | | 18.9 | | 12.4 | | 0.7 |
| EBIT | 0.0 | -45.1 | 0.0 | -35.7 | 9.2 | -4.7 |
| EBIT margin | | -172.2% | | -153.0% | | -186.6% |
| Pre-tax income | -45.2 | -45.2 | -47.5 | -47.5 | -20.7 | -7.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -45.2 | 0.0 | -47.5 | -0.1 | -20.7 | -7.4 |
| Net margin | | -0.2% | | -0.2% | | -293.6% |
| |
| Diluted EPS | ($1.72) | ($1.72) | ($3.87) | ($4.24) | ($9.45) | ($4.45) |
| Shares outstanding (diluted) | 26.3 | 0.0 | 12.3 | 0.0 | 2.2 | 1.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|